Skip to content
etf.net

Launched · SEC filings

ALPS Medical Breakthroughs ETF

SBIONYSE ArcaALPS FundsC

$53.29−1.58 (−2.88%)

As of Nov 2, 2026, 3:59 PM ET

C44/ 100

Rank 9 of 17 in Biotech & Genomics

C44/100Rank 9 of 17inBiotech & Genomics
Intraday session: down, 79 prints from 54.87 to 53.29. Range 53.12 to 55.14. Use the arrow keys to read each point.53.0054.0054.5010 AM12 PM2 PM4 PM
Expense ratio
0.50%
Fund size
$184M
1Y total return
+21.6%
Yield · Last 12 months
0.00%
Holdings
103
Avg volume · 30D
42.6K sh
52W range
low $43.10high $70.85
Launched
Filings
SEC EDGAR

The ETF.net SBIO Grade

Based on 5 of 6 pillars

C

Score 44 out of 100

Category
Biotech & Genomics⁠
Rank
9 of 17
Six-pillar profile for SBIO. Scores out of 100: Cost 38, Risk 28, Mission not scored, Tradability 50, Holdings 77, Durability 54. Strongest: Holdings (77). Weakest: Risk (28). Based on 5 of 6 pillars.

Score 44 of 100 falls in the C band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    D38 out of 100
    Rank 10 of 17

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    Not scored

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    D28 out of 100
    Rank 13 of 17

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    C50 out of 100
    Rank 7 of 17

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    A77 out of 100
    Rank 5 of 17

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    C54 out of 100
    Rank 9 of 17

Our read on SBIO

ETF.net Research

In short

CSBIO goes at biotech through a purpose-built medical breakthroughs index instead of the household benchmarks, spreading roughly 100 drug developers across one basket. A specialist route, priced at the category's middle.

Stated mandate

The fund seeks investment results that generally track, before fees and expenses, the performance of the S-Network Medical Breakthroughs Index (PMBI).

Why people hold it

  • Tracks the S-Network Medical Breakthroughs Index, a dedicated rules-based basket rather than the standard biotech benchmarks most funds in the group follow.
  • Roughly 100 holdings, so no single drug readout carries the whole fund.
  • The 0.50% expense ratio sits right at the median for biotech and genomics funds. No premium charged for the narrower mandate.
  • Trading since 2014, giving it a decade-plus of live operating history through several biotech cycles.

Worth knowing

  • Thinly traded next to the giants of the category, so spreads and limit orders matter more here than with the household names.
  • Several funds in the same biotech cohort screen stronger overall, and some cost less: IBBQ at 0.19% and XBI at 0.35% versus SBIO's 0.50%.
  • Not an income vehicle. Whatever this fund does, it does through the share prices of the drug developers it holds.

SBIO Performance

Launched Dec 30, 2014

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

SBIO$12,156
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,199
Oct 31, 2025 to Oct 30, 2026. SBIO $12,156. SPY $11,199. Use the arrow keys to read each point.$10,000$12,000$14,000$16,000Oct 2025Apr 2026Oct 2026

Oct 31, 2025 – Oct 30, 2026

Returns run to the Oct 30, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for SBIO. Periods over one year show the average yearly return.
PeriodSBIO
Year to date+7.1%
1 month−5.9%
3 months−13.4%
1 year+21.6%
3 yearsper year+32.4%
5 yearsper year+4.3%
10 yearsper year+10.6%

With distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for SBIO
YearReturn barSBIO
2026 YTD+7.1%
2025+55.1%
2024+3.8%
2023+8.7%

SBIO in the news

SBIO Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Oct 30, 2026.
0.00%Last 12 months
Payout per share
NoneLast 12 months

No distributions in the last 12 months.

Distribution history

Payments through 2024

One bar per payment. 5 payments from 2017 to 2024. Dec 21, 2017 $0.58; Dec 20, 2018 $0.78; Dec 19, 2019 $0.02; Dec 21, 2023 $0.07; Dec 19, 2024 $1.17. Use the arrow keys to read each point.20172018201920202021202220232024
Ex-datePay dateAmount per share
Dec 19, 2024Dec 26, 2024$1.17
Dec 21, 2023Dec 27, 2023$0.07
Dec 19, 2019Dec 27, 2019$0.02
Dec 20, 2018Dec 27, 2018$0.78
Dec 21, 2017Dec 28, 2017$0.58

$10,000 in SBIO 10 years ago paid $1,270 in dividends.

SBIO Risk

Risk pillarD28 out of 100Rank 13 of 17 in Biotech & Genomics
How much the fund’s monthly returns vary, scaled to a year.
28.2%
Annualised · 36 months to Oct 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
0.98
vs 3-month T-bills · to Oct 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−52.5%
Trough Oct 2023
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.95
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

FMP measures it over up to five years of monthly returns.

SBIO Cost

Compare SBIO and IBBQ

Overpaying vs IBBQ, cheapest in Biotech & Genomics

$6,027

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • SBIO 0.50%

    $9,979

  • IBBQ 0.19% Cheapest

    $3,952

$10,000
30 years

Cost over time

  • SBIO 0.50%
  • IBBQ 0.19%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$2K$4K$6K$8K$10K051015202530SBIO $9,979IBBQ $3,952

Year by year

YearSBIOIBBQOverpaying
10$900$347$553
20$3,460$1,351$2,109
30$9,979$3,952$6,027

Other funds in Biotech & Genomics

See others